Sophia Sanjay

Sophia Sanjay

@aidigihealth

3 Publicações

0 fotos

0 Vídeos

Reside em Springfield

De Mumbai City

Male

Web Marketing Executive na WiseGuy Reports

Estudou WEB MARKETING na Harvard University

Class of MBA in Healthcare

Atualizações Recentes

Sophia Sanjay @aidigihealth adicionou um novo artigo in Health
2025-11-06 10:08:05 ·

Regulatory Bodies Navigate Complexity to Accelerate Personalized Medicine Approvals; Balancing Innovation with Safety in a Dynamic Market

Regulatory approval processes are critical to the personalized medicine market’s growth, yet they face unique challenges. Unlike traditional drugs, personalized therapies often target rare genetic subtypes, have smaller patient cohorts, and rely on novel biomarkers—factors that complicate traditional efficacy and safety assessments. Agencies like the FDA, EMA, and China’s NMPA...

0 Comentários ·0 Compartilhamentos ·16 Visualizações ·0 Anterior

Faça Login para curtir, compartilhar e comentar!
Sophia Sanjay @aidigihealth adicionou um novo artigo in Health
2025-11-06 09:49:10 ·

Tech-Driven Evolution: AI and Digital Tools Reshape India’s CRO Sector for Faster Drug Development

India’s contract research organizations (CROs) are undergoing a technological revolution, with artificial intelligence (AI), machine learning (ML), and advanced analytics driving efficiency and innovation across drug development workflows. From preclinical data analysis to post-trial reporting, CROs are leveraging digital tools to reduce timelines, minimize errors, and lower costs,...

0 Comentários ·0 Compartilhamentos ·17 Visualizações ·0 Anterior

Faça Login para curtir, compartilhar e comentar!
Sophia Sanjay @aidigihealth adicionou um novo artigo in Health
2025-11-06 09:33:13 ·

Patent Expirations Ignite Generic Injectables Market Expansion: Key Drugs and Industry Responses

A wave of patent expirations for high-revenue branded injectables is propelling the generic injectables market into uncharted territory. Over the next five years, patents for drugs like adalimumab (Humira, though biosimilar), pantoprazole, and cisplatin are set to expire, opening multi-billion-dollar opportunities for generic manufacturers. This trend not only lowers patient costs but also...

0 Comentários ·0 Compartilhamentos ·15 Visualizações ·0 Anterior

Faça Login para curtir, compartilhar e comentar!

Mais Stories